Among patients with muscle-invasive bladder cancer, adjuvant Opdivo showed a continued benefit in survival versus placebo.

The 'port' - also known as a portacath or subcutaneous port – is a small, implantable device that allows chemotherapy drugs to be delivered directly into a vein. The device can be left in for ...

Conclusion: Every-three-week administration of subcutaneous darbepoetin alfa produced a complete or partial hematopoietic response in 11 of 14 women with chemotherapy- associated anemia.